Novel haemophilus parasuis disease trivalent inactivated vaccine and preparation method thereof

A technology for Haemophilus suis disease and Haemophilus suis, applied in antibacterial drugs, pharmaceutical formulations, bacterial antigen components, etc., can solve the problem of difficult to achieve immune effect, difficulty in prevention and treatment, and interactive immunity of Haemophilus parasuis serogroups. It can effectively treat and prevent Haemophilus parasuis related diseases, achieve good immune effect, and solve the problems of preparation difficulties.

Active Publication Date: 2013-02-06
PU LIKE BIO ENG
View PDF1 Cites 29 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, the mutual immunity between the various Haemophilus parasuis serogroups is not strong, and the serogroups of the vaccinated vaccine strains do not match the pathogenic serogroups of the prevailing local Haemophilus parasuis disease at that time. brought some difficulty
At present, the domestic vaccines used for the immunization and prevention of Haemophilus parasuis disease include the inactivated Haemophilus parasuis disease vaccine (Z-1517 strain) produced by Boehringer Ingelheim Animal Health (USA) Co., Ltd.; Haemophilus parasuis type 1 and 6 inactivated vaccines produced by pharmaceutical factories and Haemophilus parasuis type 4 and 6 produced by Huazhong Agricultural University, Wuhan Keqian Animal Biological Products Co., Ltd. Type 5 inactivated vaccines; the application of these vaccines has played a certain preventive role, but the pathogenic strains of the disease and multiple serotype infections have made it difficult for existing vaccines to achieve the expected immune effect, especially without parasuis. Haemophilus parasuis type 12, because there is no suitable strain preparation, and there is interference between the various antigens, one injection can prevent Haemophilus parasuis caused by the new pathogen of Haemophilus parasuis, which is an urgent problem to be solved in the breeding industry

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel haemophilus parasuis disease trivalent inactivated vaccine and preparation method thereof
  • Novel haemophilus parasuis disease trivalent inactivated vaccine and preparation method thereof
  • Novel haemophilus parasuis disease trivalent inactivated vaccine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0039] The preparation method of novel Haemophilus parasuis inactivated vaccine comprises the following steps:

[0040] a. Breeding and culturing the H. parasuis serum type 4 JS strain, type 5 ZJ strain, and type 12 HeB strain bacteria respectively to obtain type 4 JS strain bacterial fluid, type 5 ZJ strain bacterial fluid, and type 12 HeB strain bacterial fluid ;

[0041] b. Add 0.3% formaldehyde solution in total to the Type 4 JS strain bacterial liquid, Type 5 ZJ strain bacterial liquid, and Type 12 HeB strain bacterial liquid obtained in step a, respectively, place it at 37°C for inactivation, and stir for 3~ 5 times, concentrate the bacterial solution according to the counting result;

[0042] c. Mix the above-mentioned inactivated and concentrated type 4 JS strain bacterial liquid, type 5 ZJ strain bacterial liquid, and type 12 HeB strain bacterial liquid in equal proportions, and add 0.01% thimerosal in the total amount of the vaccine, and then carry out with differen...

Embodiment 1

[0047] Preparation and efficacy experiment of embodiment 1 Haemophilus parasuis trivalent inactivated vaccine

[0048] The trivalent inactivated vaccine for Haemophilus parasuis disease is prepared from the strains of Haemophilus parasuis serum type 4, 5, and 12 that have been inactivated, concentrated, and passed the safety inspection. Antigens prepared from type 4, type 5, and type 12 strains were mixed with Montanide IMS1313 VG (including the same series of adjuvants), Montanide IMS 251C VG (including the same series of adjuvants), Montanide ISA15A VG (including the same series of adjuvants), Montanide GEL PR (including the same series of adjuvants), white oil adjuvant, and aluminum hydroxide gel adjuvant are mixed to prepare the vaccine, wherein the concentration ratio of the three antigens is equal.

[0049] 1. Strains

[0050] a. Haemophilus parasuis serotype 4 JS strain, isolated and identified by Pulaike Bioengineering Co., Ltd., has been preserved in the China Center...

Embodiment 2

[0096] Example 2: Screening of the best adjuvant for Haemophilus parasuis vaccine

[0097] (1) Safety: The vaccine prepared in Example 1 was injected intramuscularly into 5 healthy susceptible pigs, each with 4 mL, and there was no local reaction within 14 days and all were healthy and alive. The test results are as follows in Table 1:

[0098] Table 1 Results of vaccine trials

[0099]

[0100]

[0101] (2) Efficacy test:

[0102] Experiments were carried out in the experimental animal room of Pulaike Bioengineering Co., Ltd. Get the vaccine prepared in Example 1, each group of vaccines uses 15 healthy susceptible pigs (raised and provided by Pulaike Bioengineering Co., Ltd. Experimental Animal Room) for each group of vaccines, and each intramuscularly injects 2 mL, containing 1 dosage After 28 days, the immune test pigs injected with each vaccine were randomly divided into three groups, and were challenged with the serotype 4, 5 and 12 strains of Haemophilus parasui...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a novel haemophilus parasuis disease trivalent inactivated vaccine and a preparation method thereof. The vaccine comprises equal proportions of antigens of: inactivated haemophilus parasuis serotype 4 JS strain, inactivated haemophilus parasuis serotype 5 ZJ strain, and inactivated haemophilus parasuis serotype 12 HeB strain. According to the invention, the haemophilus parasuis serotype 4, serotype 5, and serotype 12 strains are obtained by separation. Concentration contents and relative proportions of the antigens prepared from the three strains are subjected to large amounts of woks and practices, such that the trivalent vaccine with an appropriate antigen ratio and an appropriate concentration is obtained. The trivalent vaccine has good preventing and treating effects against haemophilus parasuis diseases caused by various epidemic haemophilus parasuis serotypes in our nation. Especially, the trivalent vaccine can solve a problem of poor treatment effect of existing vaccines caused by novel haemophilus parasuis pathogens.

Description

technical field [0001] The invention relates to a multivalent vaccine of Haemophilus parasuis, in particular to a trivalent inactivated vaccine of Haemophilus parasuis type 4 JS strain, type 5 ZJ strain and type 12 HeB strain and a preparation method thereof. Background technique [0002] Haemophilus parasuis (Hps) causes polyserositis and arthritis in pigs, also known as Glsser's Disease, which was once thought to be caused by stress The sporadic disease was later confirmed to be caused by Haemophilus parasuis. Haemophilus parasuis can affect young pigs from 2 weeks to 4 months. It mainly occurs after weaning and nursery. It is usually seen in pigs aged 5 to 8 weeks. The incidence rate is generally 10% to 15%. The mortality rate can reach 50%. The main clinical symptoms were cough, dyspnea, emaciation, lameness, and rough coat; the main necropsy lesions were fibrinous pleurisy, pericarditis, peritonitis, arthritis, and meningitis. In addition, Haemophilus parasuis can al...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/116A61K39/39A61K39/102A61P31/04
Inventor 张许科孙进忠白朝勇
Owner PU LIKE BIO ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap